Atorvia announces it has been chosen to participate in the #MassBioDrive spring 2022 cohort!
Read more here
Translating science. Transforming outcomes.
Together with world leading experts we are advancing programs to address major care gaps and significant medical need in acute care, with an initial focus on acute kidney injury (AKI). AKI is a devastating condition which affects millions, costs billions, is often deadly - and currently has no effective treatment available. To address this crisis we are developing a kidney-targeted peptide that prevents regulated cell death and kidney failure.
A Biotech with a difference, we integrate market access & commercial strategies at all stages to transform great science into life-saving technologies that regulators will approve, payers will pay and physicians will adopt.